Pyrimethamine in the Treatment of Polycythaemia Rubra Vera

Pegg, D.E.; Ford, H. T.

doi:10.1136/bmj.2.5252.617

Cited by 7 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with reports in the 1950s and 1960s (Isaacs 1954;Frost et at. 1958;Pegg & Ford 1961;Jones & Jelliffe 1963). These patients showed disease control that was comparable to that achieved with conventional chemotherapy.…”

Section: Discussionsupporting

confidence: 51%

“…The dihydrofolate reductase inhibitor Pyrimethamine (Daraprim) was used briefly for the treatment of polycythaemia rubra vera (PRV) two to three decades ago (Isaacs 1954;Frost, Jones & Jonsson 1958;Pegg & Ford 1961) but lost favour in the mid-sixties because patients treated with radioactive phosphorus e 2 p) and Busulphan were easier to manage. Consequently there are few reports on the long term use of antifolates in PRY.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pyrimethamine in the myeloproliferative disorders: a forgotten treatment?

Bowcock

Linch

Machin

et al. 1987

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Eight patients with myeloproliferative disorders, five with polycythaemia rubra vera (PRV) and three with essential thrombocythaemia (ET), have been treated with the anti-folate drug Pyrimethamine for periods ranging from 1 to 24 years. In PRV this treatment was comparable in efficacy to that achieved with Busulphan or radioactive phosphorus, but required more frequent supervision. One patient was controlled on Pyrimethamine, having failed on conventional treatment. The major side effect was thrombocytopenia which was rapidly reversible on stopping the drug. In ET, Pyrimethamine produced satisfactory control of the platelet count and thrombocytopenia did not arise. No neurological sequelae were encountered. One patient developed a non-Hodgkin's lymphoma of the gut, but there were no other cases of secondary malignancy. Pyrimethamine may still have a role in the treatment of selected cases of myeloproliferative disorders.

show abstract

Section: Discussionsupporting

confidence: 51%

mentioning

confidence: 99%